August 28, 2023 11:39 AM EDTUpdated 11:59 AM

Amgen says RNA heart drug has long-lasting effect as it races Novartis; Eli Lilly takes pill approach to same target: #ESC23

Lei Lei Wu

News Reporter

Amgen and Eli Lilly unveiled new data for their experimental heart drugs that target lipoprotein(a) — a cholesterol carrier that can increase the risk of heart …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amgen says RNA heart drug has long-lasting effect as it races Novartis; Eli Lilly takes pill approach to same target: #ESC23

Lei Lei Wu

News Reporter

Sign up to read this article for free.

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Biotech VC firm outlines plans for $100M fund

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Breaking down silos with a new quantitative approach to drug development

Am­gen says RNA heart drug has long-last­ing ef­fect as it races No­var­tis; Eli Lil­ly takes pill ap­proach to same tar­get: #ESC23

Lei Lei Wu

News Reporter

Sign up to read this article for free.

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

Biotech VC firm out­lines plans for $100M fund

Sanofi's BTK in­hibitor again slows MS pro­gres­sion, but liv­er en­zymes con­tin­ue to be tricky

Lex­i­con's pres­i­dent to step down as de­ci­sion date looms; Sarep­ta wel­comes Lil­ly, GSK vet to board

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

Amgen says RNA heart drug has long-lasting effect as it races Novartis; Eli Lilly takes pill approach to same target: #ESC23

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Biotech VC firm outlines plans for $100M fund

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Breaking down silos with a new quantitative approach to drug development